Data presented at the October 2006 Annual Scientific Meeting of NAASO, The Obesity Society, found that 60 milligrams of orlistat (Xenical), in conjunction with a reduced-calorie diet, provided significantly greater reductions in LDL cholesterol and weight when compared to treatment with a placebo and a reduced-calorie diet.
The results were based on two multicenter, double-blind, randomized, placebo-controlled clinical trials of 576 patients that were conducted over a two-year period. Study results found that approximately 38 percent of orlistat-treated participants had a favorable shift in their LDL cholesterol level compared to 11 percent in the placebo group.
Additional results showed that during the first year of the study, 45 percent more participants treated with orlistat plus a reduced-calorie diet lost at least five percent of their weight, compared to 29 percent treated with a placebo plus diet.
Orlistat works by preventing the absorption of approximately 25 percent of fat consumed. As a result of undigested fat passing through the body, users may experience gastrointestinal treatment effects.